These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28692770)

  • 41. Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs.
    Moots RJ; Mays R; Stephens J; Tarallo M
    Clin Exp Rheumatol; 2015; 33(5):737-45. PubMed ID: 26053198
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis.
    Nilsson AC; Christensen AF; Junker P; Lindegaard HM
    Dan Med Bull; 2011 Apr; 58(4):A4257. PubMed ID: 21466765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy.
    Genest G; Spitzer KA; Laskin CA
    J Rheumatol; 2018 Aug; 45(8):1109-1115. PubMed ID: 29961692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials.
    Siu S; Haraoui B; Bissonnette R; Bessette L; Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Kraft J; Lynde C; Gulliver W; Keeling S; Dutz J; Pope JE
    Arthritis Care Res (Hoboken); 2015 May; 67(6):754-64. PubMed ID: 25418272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The BeSt way of withdrawing biologic agents.
    Allaart CF; Lems WF; Huizinga TW
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
    Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
    J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.
    Harrold LR; John A; Best J; Zlotnick S; Karki C; Li Y; Greenberg JD; Kremer JM
    Clin Rheumatol; 2017 Sep; 36(9):2135-2140. PubMed ID: 28718043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
    Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
    Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.
    Einarsson JT; Geborek P; Saxne T; Kristensen LE; Kapetanovic MC
    J Rheumatol; 2016 Jun; 43(6):1017-23. PubMed ID: 27036384
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.
    Manders SH; Kievit W; Jansen TL; Stolk JN; Visser H; Schilder AM; Vonkeman HE; Adang E; van de Laar MA; van Riel PL
    J Rheumatol; 2016 Oct; 43(10):1787-1794. PubMed ID: 27481900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
    Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski M; Farley J
    J Rheumatol; 2014 Nov; 41(11):2129-36. PubMed ID: 25086079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.
    Rotar Z; Hočevar A; Rebolj Kodre A; Praprotnik S; Tomšič M;
    Clin Rheumatol; 2015 Oct; 34(10):1787-93. PubMed ID: 26345633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
    Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
    Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
    Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
    BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
    Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.